EUROPEAN JOURNAL OF CANCER欧洲癌症杂志
EUROPEAN JOURNAL OF CANCER(英文缩写 EUR J CANCER),ISSN 0959-8049,eISSN 1879-0852,中文译名:欧洲癌症杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 10.002 | Q1 |
| 2022 | 8.400 | Q1 |
| 2023 | 7.600 | Q1 |
| 2024 | 7.100 | Q1 |
| 2025 | 7.900 | Q1 |
EUROPEAN JOURNAL OF CANCER 最新收录文献
-
1. Development of an age specific EORTC questionnaire to assess the health-related quality of life (HRQOL) of children with cancer aged 8-14 years - a mixed-methods content elicitation phase I & II EORTC QLG study.
1. 开发特定年龄EORTC问卷，以评估8-14岁癌症儿童的健康相关生活质量（HRQOL）——一项混合方法内容启发阶段I和II EORTC QLG研究PMID:日期:2026-10-05Experiencing cancer can be physically and psychosocially challenging in the short- and long-term. Integrating Patient-Reported Outcome Measurements (PROMs) to capture these challenges can support patient-centered care and may reduce morbidity and mortality. However, age-appropriate tools remain scarce for children and adolescents. We report on the development phases I/II of the EORTC QLQ-CHI questionnaire tailored for children 8-14 years. Following the EORTC QLG module development guidelines, qualitative semi-structured interviews were conducted in children aged 8-14 years undergoing active cancer treatment, parents and healthcare professionals (HCPs). Participants rated the relevance of issues identified in a previous systematic review (Phase Ia) and provided preferences on response format and recall period (Phase Ib). During expert round tables, key issues were converted into items (Phase II). Interviews were completed with 47 children, 45 parents, and 22 HCPs from six countries. Among all children (mean age=10.8 ± 1.9 years; 57.4% female), 55.3% had haematological cancers. Of the initially identified issues, 57 were identified as key issues by comparing children's, parents' and HCPs feedback. Children preferred four response options (70.0%) and a shorter recall period (43.3%). Through expert round tables (Phase II), items were assigned to a more symptom-oriented core scale and an additional scale for psychosocial concerns. The provisional questionnaire consists of 50 items. This study represents the first step in developing the EORTC QLQ-CHI (8-14 years). Next steps include pilot testing, validation (Phase III and IV), co-development of a corresponding measure for children < 8 years and an observer-rating version.
-
2. Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial.
PMID:日期:2026-10-05Dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) is approved for BRAF V600E-mutated anaplastic thyroid cancer (ATC), but ∼60% of tumors do not harbor BRAF V600E, leaving these patients without effective treatment options. This was a phase 2 study of patients with BRAF wild type ATCs treated with concurrent lenvatinib 20 mg po daily and pembrolizumab 400 mg IV Q6 weeks. Those at high risk of bleeding could start on a reduced dose of lenvatinib. The primary endpoint was median OS and secondary endpoints were response rate and PFS. With a historical median OS of 3 months with single agent lenvatinib, the trial aimed to improve OS by an additional 3 months. Twenty-five patients with a median age of 62 years were enrolled, of which 64% were men. All patients had distant metastases at study entry. With a median follow-up time of 18.5 months (range 12-47.1) for alive patients, the median OS and PFS were 13 (95% CI: 7.8-35.6; p < 0.01), and 5.4 months (95% CI: 3.8-11.0), respectively. Best overall response in target lesions was 36%, including 1 complete and 8 partial responses. Lenvatinib + pembrolizumab demonstrates clinically meaningful OS in patients with metastatic, non-BRAF mutated ATC, a population with historically poor outcomes, supporting its use as an active therapeutic option. NCT04171622.
-
3. Older adults with resectable gastric cancer undergoing perioperative chemotherapy or preoperative chemoradiotherapy plus perioperative chemotherapy: A secondary analysis of the AGITG TOPGEAR phase III trial.
PMID:日期:2026-10-05To evaluate treatment adherence, adverse events, and survival in older (≥70 years) adults undergoing perioperative treatment for gastric cancer. Patients with resectable gastric/gastro-esophageal junction adenocarcinoma (ECOG 0-1) enrolled in the phase III TOPGEAR trial were randomized to perioperative chemotherapy (ECF/ECX or FLOT) alone or perioperative chemotherapy plus preoperative chemoradiotherapy (45 Gy in 25 fractions with concurrent fluoropyrimidine). In this exploratory analysis, treatment completion, grade ≥ 3 adverse events (CTCAE v3.0), surgical outcomes, overall survival (OS) and progression-free survival (PFS) were compared between older and younger adults. Of the 574 patients enrolled, 135 (24%) were ≥ 70 years. Older adults more frequently required preoperative chemotherapy dose reductions, omissions, or delays (chemoradiotherapy: 55% vs 35%, p = 0.004; chemotherapy: 60% vs 48%, p = 0.087). Rates of grade ≥ 3 adverse events were comparable between older and younger patients (chemoradiotherapy: 66% vs 67%, p = 0.874; chemotherapy: 68% vs 59%, p = 0.220), but older adults more often had hematologic toxicity and grade ≥ 3 diarrhea in the chemotherapy group (56% vs 37%, p = 0.006; 21% vs 6%, p < 0.001). Resection rates, grade 3/4 surgical complications, number of removed lymph nodes, and 30-/90-day mortality were similar by age. OS and PFS were comparable across age groups, with numerically favorable outcomes for older adults (OS: HR 0.86, 95% CI 0.58-1.26 [chemoradiotherapy]; HR 0.75, 95% CI 0.51-1.11 [chemotherapy]; PFS: HR 0.78, 95% CI 0.53-1.15 [chemoradiotherapy]; HR 0.70, 95% CI 0.47-1.03 [chemotherapy]). Older adults with gastric cancer achieved comparable oncologic outcomes to younger patients, despite more frequent treatment modifications and higher hematologic toxicity.
-
4. Diagnostic regulatory pathways are an underrecognized bottleneck in precision oncology clinical trials: Real-world evidence across Europe.
PMID:日期:2026-10-05Using real-world data (RWD), we assessed the impact of diagnostic regulatory pathways on activation timelines and biomarker testing implementation in biomarker-driven clinical trials across Europe. RWD from 132 Clinical Performance Study Applications (PSAs) and Ethics Committee (EC) submissions across 18 European Union Member States (EU-MS) and 2 non-EU countries that operate under the In Vitro Diagnostic Medical Devices Regulation 2017/746 (IVDR) were pooled for analysis. Statistical, outlier assessments and comparative analyses were performed to evaluate differences in timelines between submission pathways. Statistical significance was assessed using Welch's t-test and the Mann-Whitney U test. Mean combined approval time for all submissions (EC and PSA) was 129.39 days (median, 116.5; range 32-346). Sequential submissions averaged 139.97 days versus 121.11 days for parallel submissions, corresponding to a ∼15.6% longer timeline than sequential pathways (mean difference 18.86 days; p = 0.0411). Mean country-level combined approval timelines varied substantially across countries, ranging from 75.66 to 175 days among countries (n = 17) with ≥ 3 submissions. Substantial cross-country variability in operational implementation challenges was observed. Diagnostic approvals represent underrecognized bottlenecks in precision medicine (PM) trial activation, with approval timelines frequently exceeding those of Clinical Trial Applications (CTAs), median 108 days. Fragmented IVDR implementation has created substantial cross-country variability and uncertainty for trial activation. Biomarker strategies and diagnostic testing approaches should be thoughtfully constructed and considered pragmatically, as inefficient implementation may directly affect trial interpretability, efficacy assessment and regulatory success, substantially compromising trial delivery in Europe.
-
5. Hypomethylating agents with venetoclax for newly diagnosed acute myeloid leukemia in patients 65 and older in The Netherlands - A nationwide study of drug usage and treatment outcomes.
PMID:日期:2026-10-05For patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy the combination of a hypomethylating agent (HMA) with venetoclax (VEN) has become the standard of care. We conducted a retrospective real-world study across 15 hospitals involving patients aged ≥ 65 who were newly diagnosed with AML during the 18 months following the introduction of VEN in The Netherlands. A total of 209 patients treated with HMA + VEN as first-line therapy (median age 73.9 years, 12% ECOG ≥ 2, 26% decitabine), were included and followed for a median of 25.9 months. Composite complete remission was achieved in 69% of patients while 3-month-mortality was 15%. The median overall survival was 19.1 months (22.1, 10.9, and 6.8 months for the ELN2024 high-, intermediate- and lower-benefit groups), and 14.7 months in patients not transplanted. Transplantation, accomplished in 37 patients (18%), was associated with improved survival (HR for death 0.24; p < 0.001). Antifungal agents were used in 72% of first cycles and were associated with lower mortality (multivariable HR 0.605; p = 0.010), also leading to VEN dose reductions. A total of 101 patients (48%) received follow-up therapy (cycles 4 and onwards, median 11 cycles), 47 of which were alive at data-cutoff. Follow-up therapy was commonly initiated with 14 (55%) or 7 days (15%) of VEN. Overall, 38 patients (18%) switched to HMA monotherapy. Our findings showcase how encouraging survival outcomes can be achieved in the real world while simultaneously realizing considerable VEN savings through cycle individualization and strategic usage of drug-drug interactions.
-
6. Spectral cytometry-based immune profiling coupled with machine learning identifies circulating Th1-like cells as a blood biomarker for advanced colorectal adenomas.
PMID:日期:2026-10-05Colorectal cancer is the third most common malignancy worldwide. Although current screening relies on faecal occult blood testing (FOBT), its sensitivity for advanced adenomas (key precursor lesions) remains limited. Indeed, colonoscopy remains the gold standard for definitive diagnosis. Hence, development of novel blood-based screening tools in FOBT-positive patients is needed to optimize colonoscopy referral. We prospectively recruited 104 FOBT-positive patients undergoing colonoscopy. Based on endoscopic and histopathological assessment, patients were classified into no polyps (NP, n = 46), non-advanced polyps (NA, n = 33) and advanced polyps (AP, n = 25). Seventy-five immune cell subsets and their homing, activation and exhaustion profiles were characterized by spectral cytometry, yielding 900 variables. Differentially expressed variables were used to train five supervised machine learning models including random forest, decision tree, multinomial regression, polynomial kernel support vector machine (SVM) and Kernel K-nearest neighbours. Among 91 differentially expressed immune variables, Boruta-based feature selection identified seven key cell populations. Th1-like cells emerged as the dominant predictive variable. The decision tree model achieved the best overall performance, with total classification of AP patients (AUC=1.0, 100% sensitivity and specificity). Global model accuracy reached 75% (p < 0.01 vs. no-information rate), with a macro-AUC of 0.85. This study demonstrates that spectral-cytometry immunotyping of the circulating immunome, combined with machine learning, can identify patients harbouring advanced colorectal adenomas from a blood sample. Hence, Th1-like cells emerge not just as key cells, but also as a promising biomarker that could complement current FOBT screening to prioritize colonoscopy in patients at highest risk of pre-malignant lesions.
-
8. Systemic therapies for gastroenteropancreatic neuroendocrine carcinomas: Current paradigm and future avenues.
8. 胃肠胰神经内分泌癌的系统治疗：当前范式与未来方向PMID:日期:2026-10-05Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are aggressive, poorly differentiated neoplasms representing the most common subtype of extra-pulmonary neuroendocrine carcinomas. Despite increasing recognition, they remain biologically and therapeutically elusive, with limited understanding of their molecular drivers and few established treatment paradigms. Most patients present with advanced disease, making systemic therapy the cornerstone of management. Platinum-based chemotherapy remains the standard first-line approach, though outcomes are suboptimal and consensus is lacking regarding maintenance strategies and second-line options. Later lines of therapy are ineffective, and survival is short after progression on first-line therapy. In this review, we synthesize current evidence on systemic therapies for GEP-NECs, highlighting clinical trials of cytotoxic agents, immune checkpoint inhibitors, molecularly targeted therapies, and novel modalities such as bispecific T-cell engagers. We also discuss the role of molecular profiling and emerging biomarkers in guiding therapy, with an emphasis on precision-driven approaches for this highly heterogeneous and challenging group of malignancies.
-
10. Perspectives of people affected by cancer toward generative AI in oncology: A scoping review of applications, evidence gaps, and future priorities.
PMID:日期:2026-10-05Generative AI is increasingly being explored in cancer care, yet little is known about whether these tools align with the priorities and concerns of the people they are intended to support. We conducted a scoping review to identify studies that examined the perspectives of people affected by cancer towards generative AI. PubMed, Embase, Web of Science, and MEDLINE were searched to July 2026. Two independent reviewers screened identified records for peer-reviewed studies reporting primary empirical data on the perspectives of people affected by cancer regarding generative AI in cancer care contexts. Study characteristics, applications evaluated, and perspectives assessed were extracted and synthesised descriptively and narratively. Of 2441 records identified, 32 studies comprising 4919 participants were included. Of these, 29 assessed specific applications: 21 Patient Communication and Education, 6 Clinical Note Generation involving lay summaries, 2 Clinical Decision Support; and 3 assessed general perspectives on AI without a defined task. Where perspectives were assessed, studies predominantly measured usefulness (21/32), comprehension (20/32), and trust (14/32). People affected by cancer were generally favourable when generative AI improved the accessibility and readability of health information; however, trust was conditional on personalisation, emotional appropriateness, human oversight, and perceived accuracy. These perspectives may help inform the design and implementation of generative AI, including interface design, patient education, consent processes, workflow integration, governance, monitoring, and feedback mechanisms. Perspectives towards generative AI involving people affected by cancer remain concentrated in a narrow subset of applications. Considerations for responsible AI deployment, including safety, transparency, equity, and autonomy, have not been assessed from the perspectives of people affected by cancer.